Hansoh Pharmaceutical struck a deal with Roche to develop a portfolio of antibody-drug conjugates, extending Roche’s reach into China-powered discovery and development execution. The arrangement is positioned as co-development, reflecting how large pharma is pairing global late-stage expertise with regional early pipeline acceleration. The transaction reinforces the competitive pressure on CDMO and development ecosystems in China, particularly as ADC manufacturing scale-up and analytical development become central bottlenecks. For partners, the deal suggests continued prioritization of mechanistically diverse ADC payload and linker strategies. From a business perspective, the Roche-Hansoh collaboration is another data point in how global majors are structuring cross-border co-development to preserve speed while managing IP and regulatory pathways.